a b s t r a c t GABA A receptors are important for inhibition in the CNS where neurosteroids and protein kinases are potent endogenous modulators. Acting individually, these can either enhance or depress receptor function, dependent upon the type of neurosteroid or kinase and the receptor subunit combination. However, in vivo, these modulators probably act in concert to fine-tune GABA A receptor activity and thus inhibition, although how this is achieved remains unclear. Therefore, we investigated the relationship between these modulators at synaptic-type a1b3g2L and extrasynaptic-type a4b3d GABA A receptors using electrophysiology.
Introduction
Neurosteroids and protein kinases are among the most potent modulators of the GABA A receptor, which, when acting individually, can enhance or depress receptor function depending on the nature of the neurosteroid or protein kinase present and to some extent, on the subunit combination of the receptor (Belelli and Lambert, 2005; Moss and Smart, 1996) . However, in vivo, these agents are unlikely to be temporally discrete modulators at GABA A receptors, and are far more likely to act in concert to achieve high-precision fine-tuning of inhibitory neurotransmission.
A number of previous studies have indicated that the activity of protein kinases, and presumably phosphorylation, can modulate the potentiating effects of selected neurosteroids on both recombinant and native GABA A receptors. For example, in Xenopus oocytes expressing recombinant a1b2g2L GABA A receptors, the potentiation of GABA A receptor-mediated currents by the naturallyoccurring neurosteroid, tetrahydro-deoxycorticosterone (THDOC) is enhanced by the activation of protein kinase C (PKC) (Leidenheimer and Chapell, 1997) . These results are supported by other studies showing that inhibition of PKC and/or protein kinase A (PKA) resulted in a reduction of neurosteroid sensitivity in neurons from both the hippocampus (Harney et al., 2003) and hypothalamus (F ancsik et al., 2000) . However, whilst many studies Abbreviations: THDOC, tetrahydro-deoxycorticosterone; BIM-I, bisindolylmaleimide I; PMA, phorbol-12-myristate-13-acetate; THIP, 4, 5, 6, conducted to date support a role for protein kinases modulating neurosteroid activity at GABA A receptors, other results are apparently conflicting. Indeed, whilst the aforementioned studies collectively show positive regulation of neurosteroid potentiation by the activity of protein kinases, in both the lamina II neurons of the spinal cord (Vergnano et al., 2007) and the hypothalamic neurons of pregnant rats (Koksma et al., 2003) , enhancement of protein kinase activity causes a reduction in the neurosteroid sensitivity of GABA A receptors. This is supported by a more recent study demonstrating that, in the pyramidal neurons of the hippocampus, kindling causes an increase in GABA A receptor phosphorylation which is accompanied by a concomitant decrease in receptor sensitivity to THDOC (Kia et al., 2011) .
The reasons underling these discrepancies are currently unclear, but one factor which may affect the relationship between neurosteroids and protein kinase activity is the subunit combination of the GABA A receptor. Although the neurosteroids appear to display only modest changes in potency across most GABA A receptor subtypes (Belelli et al., 2002; Herd et al., 2007) , phosphorylation by protein kinases has been shown to differentially alter GABA A receptor function, depending on the receptor isoform , which can even distinguish between different receptor b subunits (McDonald et al., 1998) . Therefore, when acting together, it could be envisaged that protein kinases may modulate the activity of neurosteroids at the GABA A receptor in a manner that is dependent upon the receptor isoform. This may explain the variation in previous studies which have utilized different neuronal populations likely to reflect the presence of a mixture of different subsets of GABA A receptors.
In order to examine how protein kinases modulate the activity of neurosteroids in more detail, we investigated the relationship between neurosteroids and protein kinases at GABA A receptors with defined subunit compositions, replicating typical synapticand extrasynaptic-type receptor isoforms, by controlling expression in a secondary cell line. In addition, by mutating specific target residues for protein kinases on GABA A receptor subunits, we unveil a mechanism by which protein kinases can reciprocally act to modulate the actions of neurosteroids at these receptors. , g2L, g2L S327A,S343A and d GABA A receptor subunits have all been described previously (Moss et al., 1991; Connolly et al., 1996; McDonald et al., 1998; Hosie et al., 2006 Hosie et al., , 2009 . These cDNA constructs were cloned into the plasmid vector pRK5. The cDNA construct encoding murine a4
S443A was generated by site-directed mutagenesis of the wild-type a4 subunit gene using standard PCR methods and the following oligonucleotides: Forward, gccactcgccctgcatttggatctag and reverse, agctgaccccaaagaagctggc, obtained from Eurofins Genomic.
Cell culture and transfection
HEK293 cells were cultured in Dulbecco's modified Eagle medium (DMEM; Gibco) supplemented with 10% v/v foetal calf serum, 2 mM glutamine, 100 U/ml penicillin G, 100 mg/ml streptomycin and incubated at 37 C in 95% air/5% CO 2 . Cells were transfected using the calcium phosphate precipitation method (using 1 mg of each subunit cDNA and enhanced green fluorescent protein (eGFP) to a total of 4 mg): 20 ml CaCl 2 (340 mM) plus 24 ml of 2Â HBS (280 mM NaCl, 2.8 mM Na 2 HPO 4 , 50 mM HEPES, pH 7.2) per 22 mm coverslip. Cells were used for electrophysiology 24e48 h later. For biochemistry (60 mm culture dishes) cells were transfected with a total of 9 mg of the appropriate cDNA mix.
Electrophysiology
GABA-activated currents were recorded from transfected HEK293 cells continuously perfused with Krebs solution containing: 140 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl 2 , 2.52 mM Glucose, 11 mM HEPES and 5 mM CaCl 2 (pH 7.4). Whole-cell recordings were performed using patch pipettes (4e5 MU) filled with an internal solution (120 mM KCl, 1 mM MgCl 2 , 11 mM EGTA, 10 mM HEPES, 1 mM CaCl 2 and 4 mM ATP, pH 7.11) in conjunction with an Axopatch 200B amplifier (Axon Instruments). Cells were voltage clamped at À10 mV and currents filtered at 3 kHz (8 pole Bessel filter), digitized (Digidata 1322A, Molecular Devices) and viewed and analysed using Clampex and Clampfit ver 9.2, respectively (Molecular Devices). Cells were continually monitored for access resistance and discarded if this changed by >20%. Drugs were rapidly-applied using a modified U-tube system with 10e90 % response time of 100e150 msec. THDOC was prepared as a 10 mM stock solution in DMSO, and diluted to the appropriate final concentration in Krebs. The effect of the DMSO vehicle alone was negligible. The EC 20 GABA concentration was pre-determined by constructing GABA concentrationeresponse curves and new curves were generated regularly to adjust for any drift in EC 20 . The EC 20 GABA currents were recorded at 2 min intervals. The neurosteroid-mediated potentiation was measured by co-application of EC 20 GABA with 50 nM THDOC, followed by a recovery EC 20 GABA response. Recording ceased if the responses did not return to baseline GABA-activated levels. Subsequently, cells were perfused with a protein kinase inhibitor or activator diluted in Krebs solution, and applied continuously via the bath. The exceptions to this were the protein kinase G (PKG) inhibitor (KT5823) and protein kinase A (PKA) activator (cAMP), which were applied via the patch electrode. Stocks of staurosporine (1 mM), BIM-I (1 mM), KT5823 (3 mM) and phorbol-12-myristate-13-acetate (PMA; 1 mM) were prepared in DMSO. cAMP (10 mM) was dissolved in distilled water.
Western blotting
Transfected HEK293 cells were treated with 50 nM THDOC or 100 nM PMA as appropriate and were lysed to isolate total protein. Lysis buffer was supplemented with a combination of protease inhibitors (phenylmethyl sulfonyl fluoride and benzamidine) and phosphatase inhibitors (20 mM NaF, 10 mM sodium pyrophosphate and 20 nM calyculin A). Equal amounts of total protein were subjected to Western blotting to assess the expression of GABA A receptor b3 and phosphorylated b3 subunits (on S408 and S409 residues). Total protein was isolated from each transfected cell culture by homogenisation in ice-cold RIPA buffer, followed by cell disruption with repeated freezeethaw cycles. Equal amounts of total protein were subjected to sodium-dodecyl-sulphate (SDS) polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Blotting was performed using 5% w/v milk, or 0.2% BSA, in 0.1% v/v TWEEN-supplemented TRIS-buffered saline (TBS), with blocking for 1 h at room temperature (RT), exposure to primary antibody overnight at 4 C, and secondary horseradish peroxidase (HRP)-conjugated antibody for 1 h at RT. Following incubation with each antibody, membranes were washed 3Â (10 min, RT) with phosphate buffered saline (PBS) and imaged using the ECL detection system (GE Healthcare). Images were quantified using the Western blot plug-in on ImageJ software (Version 1.44p, National Institutes of Health, USA).
Antibodies
The following primary antibodies were used for Western blotting: Rabbit antib3-GABA A receptor (1:1000 dilution, Millipore), Rabbit anti-phospho-b3-GABA A receptor (1:1000, phosphorylated S408/409 epitope, gift from Dr J Jovanovic, UCL, UK). A donkey anti-rabbit (1:2500, GE Healthcare) secondary antibody (IgG (H&L)) conjugated to HRP was subsequently used for detection.
Data analysis and statistics
Peak whole-cell GABA-activated currents were analysed using Clampfit ver 9.2. For protein kinase inhibitor or activator experiments, current responses were normalized to the first response elicited by EC 20 GABA. The potentiation caused by a neurosteroid was measured relative to the preceding response to EC 20 GABA and expressed as a percentage. All concentration response curves were constructed by plotting mean peak response amplitude against GABA concentration and the data subsequently fitted with the Hill equation:
where I ¼ GABA-activated current, EC 50 ¼ concentration of GABA inducing 50% of the maximal current response and n is the Hill coefficient. Data were graphically represented and analysed using Origin version 6.0 (Microcal). Statistical analyses were undertaken using GraphPad Instat (v.3) employing either a student's t-test (two value comparisons) or an ANOVA (three or more value comparisons) followed by an appropriate post-hoc test (as stated in the text) to compare selected data sets.
Results
To examine the effects of phosphorylation by protein kinases on the potentiation of typical synaptic GABA A receptors by neurosteroids, HEK293 cells were transfected to express a1b3g2L subunit-containing GABA A receptors. Whole-cell recording was used to assess the magnitude of neurosteroid-mediated potentiation before and after cells were treated with modulators to inhibit or activate protein kinase activity. Peak currents were recorded in response to brief (3 s) applications of either EC 20 (the concentration eliciting 20% of the maximal GABA response) GABA alone, (baseline control responses), or EC 20 GABA co-applied with 50 nM of the neurosteroid, THDOC (the potentiated GABA responses). At this concentration neurosteroids act to potentiate GABA A receptor currents. Higher concentrations in the region of 1 mM and above induce proportionately more direct activation of the receptor in the absence of agonist.
4. THDOC potentiation at a1b3g2L GABA A receptors is reduced following protein kinase inhibition To investigate whether neurosteroid-mediated potentiation could be modulated by protein kinases, cells were treated with staurosporine (200 nM), selected as it is broad-spectrum nonspecific protein kinase inhibitor. Staurosporine was also chosen because it is cell permeable, which allows the potentiation induced by THDOC to be measured before and after treatment within the same cell, thus reducing any potential variation in results that could arise from using separate populations of treated and untreated cells. For each cell, the baseline response to EC 20 GABA alone and the potentiated response after co-application of EC 20 GABA and 50 nM THDOC was established under basal conditions (i.e., before protein kinase inhibitor treatment; Fig. 1A ). Cells were then treated with 200 nM staurosporine, applied continuously via the bath perfusion. After 14 min, the baseline and potentiated responses were re-measured. To allow a direct comparison of the potentiation before and after staurosporine treatment, each potentiated response was normalised to the cell's preceding response to EC 20 GABA alone. For control experiments, cells remained untreated for the duration of the recording and these showed negligible change in the potentiation elicited by 50 nM THDOC over 30 min (2.5 ± 7.9%; n ¼ 6; Fig. 1A and C). By contrast, cells treated with staurosporine exhibited a significant decrease in THDOC-mediated potentiation of 54.8 ± 9.1% (P < 0.05, paired t-test; n ¼ 5; Fig. 1A and C). This decrease in potentiation was not caused by a staurosporinemediated shift in the GABA concentrationeresponse relationship, which remained unchanged (data not shown). Notably, the potentiation by THDOC was not completely abolished, (45.5 ± 12.7% remained after staurosporine treatment: Fig. 1AeC ), indicating that whilst THDOC-mediated potentiation of recombinant a1b3g2L GABA A receptors is modulated by protein kinases, the presence of activated protein kinases per se, is not an absolute requirement for neurosteroid potentiation.
THDOC-mediated potentiation is modulated by PKC
The GABA A receptor is a target for phosphorylation by a number of serineethreonine protein kinases, including PKA, PKC, PKG and CaMKII Brandon et al., 2002) . To identify the roles that specific protein kinases play in modulating the potentiation of the GABA A receptor by neurosteroids, we treated cells with selective kinase inhibitors or activators. PKC activity was inhibited using 500 nM bisindolylmaleimide I (BIM-I: Fig. 2 ). Cells treated with BIM-I (for 40 min) exhibited a significant decrease in THDOC-mediated potentiation (by 43.5 ± 3.8%, P < 0.05, paired ttest; n ¼ 5; Fig. 2A and C). By contrast, inhibition of PKA with an inhibitor peptide (500 nM PKAI), or PKG with the selective inhibitor KT5823 (3 mM), did not alter neurosteroid potentiation (Supplementary Fig. 1 ) indicating that potentiation of a1b3g2L GABA A receptors by THDOC is modulated primarily by PKC. As observed with staurosporine, the potentiation was not abolished after BIM-I treatment ( Fig. 2) , further suggesting that protein kinases are not required for basal potentiation by neurosteroids.
Activation of PKC enhances THDOC-mediated potentiation
To further examine the relationship between PKC and neurosteroid modulation of GABA A receptors, the effects of activating PKC were investigated. For this we used phorbol-12-myristate-13-acetate (PMA). Cells treated with 100 nM PMA (for 36 min) resulted in a significant increase in THDOC-mediated potentiation (by 58.0 ± 18.3%; P < 0.05, paired t-test; n ¼ 6; Fig. 3A ). This increase was not due to a PMA induced shift in the GABA concentrationeresponse relationship which remained unchanged (data not shown). We also investigated the effects of activating PKA using cAMP (300 mM) but, contrastingly, this did not significantly alter neurosteroid potentiation (À9.0 ± 4.4%, P > 0.05; n ¼ 4; Fig. 3B ). These observations support those which used the broadspectrum protein kinase inhibitor staurosporine, and selective inhibitor BIM-I, and indicate that THDOC-mediated potentiation of a1b3g2L GABA A receptors is primarily modulated by PKC.
The concentration of neurosteroids present in vivo is not static but instead undergoes dynamic changes in response to various physiological and pathophysiological conditions including stress, pregnancy, the ovarian cycle and ageing (Purdy et al., 1991; Paul and Purdy, 1992; B€ ackstr€ om et al., 2003; Schumacher et al., 2003; Sanna et al., 2009) , as well as in response to administration of selected psychoactive drugs, such as ethanol, g-hydroxybutyrate (GHB) and anti-depressants including fluoxetine (Uzunov et al., 1996; Sanna et al., 2004) . With this in mind, we performed similar experiments using varying concentrations of THDOC (0.1e100 nM) in order to establish whether PKC can reciprocally modulate the actions of neurosteroids across a range of concentrations. Consistent with previous data, THDOC concentrations of 10 nM and above were able to significantly potentiate a1b3g2L GABA A receptor function (% potentiation ¼ 12.0 ± 3.5 (10 nM), 66.2 ± 10.0 (50 nM), 111.5 ± 17.2 (100 nM); P < 0.05, paired t-test; n ¼ 5e11; Fig. 4 ). No significant potentiation was observed in cells exposed to 1 nM or less THDOC (5.3 ± 4.3%, P > 0.05; n ¼ 8; Fig. 4 ). After treatment with 100 nM PMA (for 30 min), potentiation by 1, 10, 50 and 100 nM THDOC was significantly enhanced by 102.3 ± 43.2%, 152.7 ± 65.4%, 50.8 ± 14.2% and 34.8 ± 14.2%, respectively (P < 0.05, paired t-test; n ¼ 5e11; Fig. 4 ). It therefore seems that phosphorylation by PKC can modulate THDOC-mediated potentiation across a broad physiological range of neurosteroid concentrations likely to be experienced in vivo. Interestingly, treatment with PMA revealed that potentiation could be elicited by just 1 nM THDOC under conditions of increased PKC activity, which previously was subthreshold for potentiation (Fig. 4) .
Phosphorylation at the b3 subunit is important for modulating THDOC-mediated potentiation
To explore the mechanism by which PKC modulates the activity of neurosteroids at GABA A receptors and, in particular, to examine the involvement of direct receptor phosphorylation in this process, HEK293 cells were transfected to express a1b3g2L GABA A receptors containing single or multiple point mutations of consensus phosphorylation sites known to be targeted by PKC, namely S408 and S409 on b3 subunits, and S327 and S343, on g2L subunits. Similar to the results obtained for wild-type receptors, THDOC-mediated potentiation at a1b3 S408A g2L, a1b3 S409A g2L (Fig. 5AeC ) and a1b3g2L S327A,S343A ( Supplementary Fig. 2 ) GABA A receptors was significantly reduced after treatment (14 min) with 200 nM staurosporine (decrease in potentiation ¼ 36 ± 7.5, 54 ± 6.9% and 50.3 ± 7.5%, respectively, P < 0.05, paired t-test; n ¼ 4e5). By contrast, cells expressing a1b3 S408A,S409A g2L GABA A receptors showed no change in the magnitude of the potentiation elicited (À1.74 ± 8.7%, P > 0.05; n ¼ 5; Fig. 5AeC ). This complete removal of sensitivity to kinase inhibition implies that phosphorylation at the b3, but not the g2L subunit, is important for the PKC-mediated modulation of neurosteroid potentiation at a1b3g2L GABA A receptors. Furthermore, the requirement to remove both S408 and S409 in order to abolish the staurosporine-induced decrease in THDOC-mediated potentiation, suggests that phosphorylation at either b3 S408 or S409 is sufficient to modulate the actions of neurosteroids at these receptors. Interestingly, under basal cell conditions (i.e., before staurosporine treatment), the magnitude of potentiation elicited by 50 nM THDOC at a1b3 S408A,S409A g2L GABA A receptors was significantly reduced compared to that induced at wild-type receptors (48.6 ± 10.8% versus 99.1 ± 13.8%, P < 0.05, ANOVA with Tukey's post hoc test; n ¼ 5e6; Fig. 5A , C). This decrease may be due to the b3 subunit (wild-type or either of the single mutants) being basally phosphorylated, a post-translational modification that cannot occur at the doubly mutated subunit. Therefore, as the magnitude of potentiation was reduced under conditions where this subunit cannot be phosphorylated, this supports the notion that phosphorylation at the b3 subunit is important for regulating neurosteroid activity at a1b3g2L GABA A receptors.
8. Phosphorylation by PKC at b3 S408 or S409 is sufficient to modulate neurosteroid activity
We have shown that THDOC-mediated potentiation at a1b3g2L
GABA A receptors is specifically modulated by PKC (Fig. 2) . We therefore investigated whether the b3 subunit S408 and S409 residues are targeted specifically by PKC by using either 100 nM PMA or 500 nM BIM-I, in order to specifically activate or inhibit PKC, respectively. Following treatment with 100 nM PMA, cells expressing a1b3
S408A
g2L or a1b3
S409A
g2L GABA A receptors exhibited significant enhancements in THDOC-mediated potentiation (54.6 ± 13.8% and 61.1 ± 37%, respectively: P < 0.05, paired ttest; n ¼ 4; Fig. 6B ), similar in magnitude to the increase observed at wild-type receptors. By contrast, potentiation at a1b3 S408A,-S409A g2L receptors was unaffected by treatment with either PMA (Fig. 6A and B: À7.3 ± 9.0%; P > 0.05; n ¼ 4e5) or BIM-I ( Fig. 6C and D; 1.6 ± 8.3%; , P > 0.05; n ¼ 4e5), indicating that these residues are important for the modulatory effects of PKC observed previously. These results support those obtained using staurosproine and BIM-I, demonstrating that PKC-mediated phosphorylation specifically at b3 S408 and S409 is sufficient to modulate the magnitude of potentiation elicited by 50 nM THDOC at a1b3g2L GABA A receptors.
The PKC inhibition experiments ( Fig. 6C and D ) also show that, under basal cell conditions, the magnitude of THDOC-mediated potentiation induced at a1b3 S408A,S409A g2L GABA A receptors is significantly reduced compared to that observed at wild-type receptors (45.7 ± 12.9% compared to 140.6 ± 19.2%, respectively, P < 0.05, paired t-test; n ¼ 4e5). This supports the idea that basal phosphorylation at the wild-type receptor, which is eliminated from the double mutant receptor, results in an apparent enhancement in the level of potentiation elicited by 50 nM THDOC. In support of this, it is notable that in the PKC activation experiment, there was a trend for the THDOC (50 nM) potentiation elicited at wild-type receptors (70.2 ± 17.3% enhancement of the EC 20 GABAactivated current) to be greater than that at a1b3 S408A,S409A g2L
GABA A receptors (48.8 ± 6.5%; Fig. 6B ), though this did not reach significance. GABAactivated responses elicited by THDOC (0.1e100 nM) before (black bars) and after (grey bars) 100 nM PMA (n ¼ 5e11). All data points represent mean ± s.e.m. *P < 0.05, paired t-test.
Basal phosphorylation is not required for THDOC-mediated potentiation
To further explore the requirement for protein kinase activation in the modulation of GABA A receptors by neurosteroids, the magnitude of potentiation elicited by 50 nM THDOC was assessed in cells expressing a1b3 S408A,S409A g2L S327A,S343A GABA A receptors, effectively eliminating basal PKC-induced phosphorylation at all known PKC sites within the receptor. Consistent with the protein kinase inhibition experiments, potentiation was still observed at these receptors (data not shown), indicating that phosphorylation by protein kinases is not required for the potentiation of GABA A receptor function by neurosteroids.
THDOC enhances b3 subunit phosphorylation via an interaction with the GABA A receptor
The experiments conducted throughout this study have focused on the ability of phosphorylation, by protein kinases, to modulate the actions of neurosteroids at GABA A receptors. However, this reflects just one aspect of this relationship and does not address the potential for this modulation to be bi-directional, i.e., can neurosteroids affect the extent of phosphorylation of the GABA A receptor? To investigate this, Western blot analysis was used to determine the extent of b3 subunit phosphorylation in HEK293 cells expressing a1b3g2L GABA A receptors, before and after exposure to a neurosteroid. Cells either remained untreated or were exposed to 50 nM THDOC for 5, 10 or 20 min. Lysates were probed in duplicate with both b3 and phospho-b3 anti-sera and, for each treatment group, the level of phosphorylated b3 was normalized to the corresponding amount of total b3 present. As expected, no phosphorylated b3 was detected in cells expressing a1b3 S408A,-S409A g2L (Fig. 7A lane 1) and both b3 and phosphorylated b3 were predictably not detected in cells expressing just a1 and g2L subunits ( Fig. 7A lane 2) , confirming the specificity of antibodies for their respective targets.
Experiments performed on untreated cells confirmed that there is some basal phosphorylation of the b3 subunit when it is coexpressed with a1 and g2L in HEK293 cells (Fig. 7A lane 3) . After treatment of cells with 50 nM THDOC for 5 min, there was little change in the level of b3 subunit phosphorylation (10.7 ± 11.6% increase, P > 0.05; n ¼ 3; Fig. 7A lane 4, Fig. 7B ). A tendency towards increased phosphorylation was detected in cells treated with THDOC for 10 min (78.7 ± 34.9%, P > 0.05; n ¼ 3; Fig. 7A lane 5, Fig. 7B ), and cells exposed to THDOC for 20 min exhibited a significant enhancement in the extent of b3 subunit phosphorylation of 96.3 ± 27.9% (P < 0.05, ANOVA with Dunnett's post hoc test; n ¼ 3; Fig. 7A lane 6, Fig. 7B ). Of interest, this level of phosphorylation was still significantly less than that achieved by combining a slightly longer incubation time of THDOC (30 min) with 100 nM PMA (Fig. 7A, lane 7) . Collectively, these results indicate that THDOC can enhance b3 subunit phosphorylation, supporting the presence of a reciprocal transduction pathway in which neurosteroids can themselves modulate the phosphorylation of the a1b3g2L GABA A receptor. This in turn may modify the ability of specific kinases to further potentiate the receptor. In order to examine whether THDOC acts to enhance receptor phosphorylation through an interaction with the GABA A receptor, we repeated our experiments using cells expressing a1 Q241W b3g2L GABA A receptors. We previously determined that this mutation is critically responsible for the sensitivity of GABA A receptors to potentiating concentrations of neurosteroid (Hosie et al., 2006) . In untreated cells, basal phosphorylation was still evident at the b3 subunit ( Fig. 7C lane 3) , indicating that these receptors can be normally phosphorylated. However, following exposure to 50 nM THDOC for 5, 10 or 20 min, no significant alteration in the level of b3 subunit phosphorylation was observed (Changes: -2.7 ± 18.4%, 25.0 ± 22.7% and 9.3 ± 27.4%, respectively, P > 0.05; n ¼ 3; Fig. 7C lanes 4e6, Fig 7D) . Notably, 100 nM PMA (30 min) was still able to significantly phosphorylate the a1 Q241W b3g2L receptor (Fig. 7D ).
These results suggest that THDOC acts to modulate GABA A receptor phosphorylation through a direct interaction with the receptor complex. Furthermore, as the mutation Q241W is sufficient to eliminate any enhancement in receptor phosphorylation by neurosteroid, it is apparent that occupancy of the potentiating neurosteroid binding site is necessary to facilitate this reciprocal modulation. Collectively, these results show that a complex, bi-directional relationship exists between neurosteroids and protein kinases at the a1b3g2L GABA A receptor, with phosphorylation at the receptor acting to positively modulate the actions of neurosteroids and, in the reverse direction, exposure to neurosteroids enhancing the extent of receptor phosphorylation.
THDOC potentiation at a4b3d GABA A receptors is reduced by protein kinase inhibition
In order to investigate whether the activity of protein kinases is also important for regulating the magnitude of neurosteroid potentiation at extrasynaptic-type receptors, HEK293 cells were transfected to express a4b3d subunit-containing GABA A receptors. To ensure that the expressed receptors contained the d subunit, sensitivity to the agonist, 4,5,6,7-tetrahydroisothiazolo-[5,4-c]pyridine-3-ol (THIP) was examined. THIP has been shown to exhibit super-agonist activity at d subunit-containing receptors compared to its partial agonism at abg receptors (Brown et al., 2002; Storustovu and Ebert, 2006; Mortensen et al., 2010) . We therefore used this agonist as a reliable indicator for the presence of d subunits within the receptor complex. The results showed that 100 mM THIP-induced currents were significantly larger than those elicited by 100 mM GABA, indicating incorporation of the d subunit (data not shown).
To determine whether the actions of neurosteroids at a4b3d GABA A receptors could be modulated by the activity of protein kinases, cells were treated with the broad-spectrum protein kinase inhibitor, staurosproine (200 nM) for 14 min. Staurosporine significantly reduced the potentiation induced by 50 nM THDOC (decrease: 38.1 ± 5.8%, P < 0.05, paired t-test; n ¼ 9; Fig. 8AeC ). We deduce that the actions of neurosteroids at a4b3d GABA A receptors can therefore also be modulated by the activity of protein kinases.
Furthermore, as observed with a1b3g2L GABA A receptors, protein kinases are not required for the induction of THDOC-mediated potentiation at these receptors, as 50 nM THDOC remained able to enhance the EC 20 GABA-activated current by 83.7 ± 18.5% after staurosporine treatment (Fig. 8AeC) .
A number of studies have reported that GABA A receptors incorporating the d subunit are more sensitive to the potentiating actions of neurosteroids (Belelli et al., 2002; Brown et al., 2002; Wohlfarth et al., 2002) . However, in the present study, the magnitude of potentiation elicited by 50 nM THDOC at a4b3d GABA A receptors did not differ significantly from that observed at a1b3g2L
receptors (128 ± 23.6% and 99.1 ± 13.8%, respectively, P > 0.05; n ¼ 5e9; Fig. 8 compared to Fig. 1 ).
12. Phosphorylation of b3 subunits alone does not account for protein kinase modulation of THDOC potentiation at a4b3d GABA A receptors
For synaptic-type a1b3g2L GABA A receptors, the extent of b3 subunit phosphorylation regulates the magnitude of neurosteroid potentiation ( Fig. 5 and 6 ). Equally, phosphorylation at the b3 subunit may also be important for the modulation of neurosteroid activity at extrasynaptic-type a4b3d receptors. To this end we expressed GABA A receptors containing mutant b3
S408A,S409A subunits, in combination with wild-type a4 and d. Surprisingly, following staurosporine treatment, a4b3
d GABA A receptors still exhibited a significant reduction in THDOC-mediated potentiation (27.2 ± 4.6%, P < 0.05, paired t-test; n ¼ 9; Fig. 9 ), comparable to that seen with a4b3d receptors, an effect which was not observed in the equivalent synaptic-like receptor (Fig. 5C) .
Therefore it appears that phosphorylation at the b3 subunit is not the sole determinant of neurosteroid potentiation by protein kinases in a4b3d receptors. However, staurosporine was notably less effective at a4b3
d GABA A receptors compared to a1b3g2L
single mutants (Fig. 5C) , with a smaller decrease in potentiation being observed at these compared to wild-type receptors (27.2 ± 4.6% versus 38.1 ± 5.8%; Fig. 9B ). This suggests that phosphorylation at the b3 subunit may play a role in the modulation of neurosteroid activity at a4b3d receptors, but that phosphorylation at this subunit is insufficient to completely account for the modulatory effects of protein kinases observed at wild-type extrasynaptic-type receptors. Therefore, phosphorylation at other residues and/or subunits may also be important for the regulation of neurosteroid potentiation at this receptor subtype. . Responses were normalised to the peak current recorded at 2 min. *P < 0.05, paired t-test.
13. Phosphorylation of a4 and b3 subunits regulate neurosteroid activity at a4b3d GABA A receptors
Another PKC phosphorylation site is known to exist on the a4
subunit, at serine 443 (Abramian et al., 2010) , which is absent from other members of the a subunit family (Moss et al., 1992; Moss and Smart, 1996) . This residue has recently been found to be responsible for the increased expression of a4 subunit-containing extrasynaptic receptors following exposure to neurosteroid (Abramian et al., 2014) . To explore the involvement of a4 S443 in the modulation of neurosteroid potentiation in our study, we used an S443A mutation to prevent phosphorylation at this site. Similar to the results obtained for a4b3
S408A,S409A
d GABA A receptors, cells expressing a4 S443A b3d exhibited a significant decrease in THDOC-mediated potentiation following treatment with 200 nM staurosporine (for 14 min: 24.5 ± 4.3%, P < 0.05, paired t-test; n ¼ 7; Fig. 10 ). By contrast, for a4
d receptors, staurosporine was now ineffective as the magnitude of potentiation elicited by 50 nM THDOC was unaffected by staurosporine treatment (0.9 ± 6.5%, P > 0.05; n ¼ 7; Fig. 10 ). Thus, phosphorylation at both the a4 and b3
subunits must be abolished in order to fully prevent the staurosporine-induced decrease in THDOC potentiation. This suggests that phosphorylation at both a4 and b3 subunits is important for regulating neurosteroid activity at a4b3d GABA A receptors.
However, as neurosteroid potentiation was still evident at
d GABA A receptors, (50 nM THDOC, 89.7 ± 15.3% enhancement of the EC 20 GABA-activated current: Fig. 10 ), this confirms that, as for the synaptic GABA A receptor counterpart, phosphorylation by protein kinases is not absolutely required to induce THDOC-mediated potentiation at extrasynapticlike a4b3d GABA A receptors.
Discussion
Neurosteroids are potent modulators at the GABA A receptor, potentiating GABA-mediated responses at low concentrations, and thereby enhancing levels of inhibition, but also directly activating the receptor at higher, often non-physiological concentrations (Belelli and Lambert, 2005) . Specific residues that are common to all GABA A receptor a subunits are responsible for these potentiating actions (Hosie et al., 2006 (Hosie et al., , 2009 . As endogenous modulators of GABA A receptor function, neurosteroids play an important role in mediating the stress response, and inducing anxiolysis or sedation, a phenotype that may feature during pregnancy or the ovarian cycle, when neurosteroid levels increase manifold (B€ ackstr€ om et al., 2003; Belelli and Lambert, 2005; Purdy et al., 1991; Maguire and Mody, 2007) . This in turn can induce cyclic changes in d subunit expression and a concurrent modulation of tonic inhibition in specific brain regions such as the dentate gyrus (Maguire and Mody, 2007) . Protein kinases are also potent modulators of GABA A receptor function in a bi-directional manner, achieved by targeting specific residues for phosphorylation. One of the more significant modulators is PKC which targets known serine residues to modulate GABA-mediated responses Krishek et al., 1994; Lin et al., 1996; Leidenheimer and Chapell, 1997; Jovanovic et al., 2004; Brandon et al., 2000) . Given that these endogenous modulatory mechanisms operate ubiquitously within and around CNS neurons, it is very likely that they will interact and may be synergistic in their modulation of GABA A receptor function, especially during times of stress when neurosteroid levels are elevated.
There are many precedents for a positive synergistic interaction of the naturally-occurring neurosteroid, THDOC, and protein kinases (Leidenheimer and Chapell, 1997; F ancsik et al., 2000; Harney et al., 2003) , though equally there is evidence to the contrary (Koksma et al., 2003; Vergnano et al., 2007; Kia et al., 2011) . This inconsistency may reflect the responses of different receptor subtypes to both neurosteroids and protein kinases (Belelli et al., 2002; Herd et al., 2007; Moss and Smart, 1996) . With this in mind we have determined how both typical synaptic-(a1b3g2L) and extrasynaptic-type (a4b3d) receptor modulation by neurosteroid is influenced by the activity of protein kinases typical of neuronal cells.
We noted in this study that both synaptic and extrasynaptic recombinant receptor isoforms were equally sensitive to neurosteroid, with EC 20 concentrations of GABA potentiated by~100% with 50 nM THDOC, underlying the consistency of the THDOC effect among receptor isoforms. Equally, the potentiated responses of both receptor types were sensitive to the broad-spectrum kinase inhibitor staurosporine, which typically inhibited by up to 50%. This demonstrates a consistent inhibition of the potentiating neurosteroid action by protein kinases, and also reinforces the instrumental role basal protein kinase activity plays in controlling the ability of neurosteroids to potentiate at these receptor isoforms. The similar level of potentiation observed with both types of GABA A receptor is not surprising given that the neurosteroid binding site is conserved on all a subunits (Hosie et al., 2009 ) and these are common to extrasynaptic and synaptic receptors. Nevertheless, it is plausible that the neurosteroid allosteric modulation can be affected by other subunits in the pentamer. However, the sensitivity of extrasynaptic GABA A receptors to neurosteroids, many of which will contain d subunits, displays variability, and the underlying conditions causing this variation are yet to be established (Wang, 2011; Wohlfarth et al., 2002) . By searching for a mechanism, using specific kinase inhibitors and activators, we establish that PKC is largely responsible for these actions on synaptic receptors. Importantly, the activity of PKC is able to modulate THDOC potentiation over a broad spectrum of physiological concentrations of this neurosteroid. Candidate residues for phosphorylation by PKC have previously been identified as neighbouring serines 408 & 409 on the b3 subunit (Moss et al., 1992; McDonald and Moss, 1997) . Mutating these residues individually in the synaptic-type receptor was insufficient to ablate the specific effects of PKC modulation, but substitution of both serines (b3 S408A,S409A ) prevented any modulation of THDOC potentiation by the both PMA and BIM-I. Clearly, both these residues are targeted by PKC for phosphorylation under both basal and enhanced phosphorylation conditions, and in order to establish the enhanced potentiation observed with 50 nM THDOC. The specificity of this synergistic interaction for this synaptic receptor was confirmed by Western blotting following substitution of S408 and S409, and the potentiating neurosteroid binding site, a1
Q241
. Clearly, the phosphorylation status of the synaptic receptor (a1b3g2) is very important in revealing the full effect of THDOC, as increased phosphorylation enhances the actions of THDOC, whereas inhibition of phosphorylation impairs it.
Equally, our studies using staurosporine also revealed the same synergistic mechanism at work for extrasynaptic-like GABA A receptors (a4b3d). However, for this isoform, modulation of THDOC potentiation by protein kinase not only occurs via phosphorylation of S408 and S409 on the b3 subunit, but also occurs simultaneously via S443 on the a4 subunit, as only on the triple mutant receptor (a4 S443A b3 S408A,S409A d) is staurosporine ineffective. In fact, the a4 S443 site is exclusively phosphorylated by PKC, rather than by other kinases (Abramian et al., 2010) . It is of interest to note that a1 and a4 subunits can also assemble with b2 subunits (Sieghart and Sperk, 2002; Olsen and Sieghart, 2009 ) and the latter are also substrates for PKC phosphorylation at S410 , which may also influence the extent of neurosteroid potentiation.
Collectively, our data suggest that THDOC can enhance GABAactivated currents at both synaptic and extrasynaptic receptors in a phosphorylation-independent manner, since by inhibiting PKC activity THDOC potentiation is reduced, though never abolished. However, as well as being inhibited, THDOC potentiation can also be augmented by the phosphorylation state of these receptors through the specific activation of PKC. Notably, b3 S408,S409 and a4 S443 are specifically targeted by PKC for phosphorylation (Abramian et al., 2010) , and indeed, it has recently been suggested that THDOC may promote the activity or recruitment of PKC isoforms associated with the receptor, especially a4 subunitcontaining receptors, in order to assist receptor phosphorylation (Abramian et al., 2014) . We clearly show that residues b3 S408,S409 are both targets for PKC modulation of the THDOC potentiation, though additionally a4 S443 is also key in a4 subunit-containing extrasynaptic receptors. Current evidence suggests that only the a4 S443 residue of extrasynaptic receptors is targeted for THDOCinduced phosphorylation by PKC to increase cell surface GABA A receptor expression/stability, to bring about enhanced tonic (THIPactivated) currents in hippocampal slices (Abramian et al., 2014) .
The contribution made by b3 S408,S409 to tonic neuronal currents is yet to be assessed, though, surprisingly, a1b3 cell surface levels were unaffected by THDOC. In our current study, total expression levels of b3 subunits in HEK cells, as part of the a4b3d heteropentameric receptor, were unchanged after THDOC.
In conclusion, we find that phosphorylation of residues b3 S408,S409 in addition to a4 S443 in extrasynaptic receptors is a prerequisite for full THDOC-induced potentiation of GABA responses, and this must involve a signal transduction pathway linking the first a-helical transmembrane domain (M1) in the a subunits (location of a neurosteroid binding site) with the large intracellular region between M3 and M4 (sites for phosphorylation). We may speculate that although the M3-M4 loop lacks a defining physical structure to date, the interaction between neurosteroids and protein kinases may suggest this domain has a much closer association with the membrane based M1-M4. It also argues that other interacting molecules with the M3-M4 loop (receptor- associated proteins) and post-translational modifications (e.g., ubiquitination) may also have as yet undisclosed effects on neurosteroid potentiation.
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